Navigation Links
Lilly Declares Fourth-Quarter 2013 Dividend
Date:10/21/2013

INDIANAPOLIS, Oct. 21, 2013 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2013 of $0.49 per share on outstanding common stock.

The dividend is payable December 10, 2013 to shareholders of record at the close of business on November 15, 2013.

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs.  Additional information about Lilly is available at www.lilly.com.  F-LLY

Refer to: (317) 276-5795 Mark Taylor

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO )


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Lilly Reintegration Scholarship Applications Available for 2014-2015 Academic Year
2. Lilly to host investment community meeting at its Indianapolis headquarters on Thursday, October 3, 2013
3. Data Presented at 49th EASD Annual Meeting Show Treatment with Lillys Investigational Dulaglutide Resulted in Improved Patient-Reported Health Outcomes
4. Lilly Announces Second Positive Ramucirumab Phase III Gastric Cancer Study Meets Primary Endpoint; Phase III Lilly/TRIO Breast Cancer Study Misses Primary Endpoint
5. Exosome Diagnostics Enters Collaboration Agreement with Lilly for Exosome Blood-Based Biomarker Discovery
6. Lilly to Present Data Across its Diabetes Portfolio at the 49th European Association for the Study of Diabetes Annual Meeting
7. Humana and Lilly Form Research Collaboration to Improve Health Care Outcomes
8. Dr. Marschall S. Runge Elected to Lilly Board of Directors
9. Lilly Reports Second-Quarter 2013 Results
10. After Reviewing Brief Product Profiles, Surveyed Physicians Believe that Likely Candidates for Late-Phase Chronic Kidney Disease Products from AbbVie, Mitsubishi Tanabe, Eli Lilly, Concert, Fibrogen and Pfizer are Typically Stage 3b and 4 Patients
11. Lilly Disappointed in Draft Medicare Coverage Decision for Beta-Amyloid Imaging Agents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... , March 29, 2017 Wound care ... promote healing of the wound. The industry mainly consists ... products for the treatment of wounds caused by mechanical, ... due to diseases such as diabetes, skin related diseases, ... Europe was the largest region in ...
(Date:3/29/2017)... DUBLIN , Mar. 29, 2017 Research ... Chromatograph Market 2017-2021" report to their offering. ... The global gas chromatograph market ... The report, Global Gas Chromatograph Market 2017-2021, has ... industry experts. The report covers the market landscape and its growth ...
(Date:3/29/2017)... 2017 Avelas Biosciences, Inc., a clinical stage oncology-focused company ... announced that Carmine N. Stengone , president and chief executive ... & Company 16 th Annual Healthcare Conference on Wednesday, April ... Westin Grand Central Hotel in New York City ... ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... 2017 , ... Full Contact K9, an Atlanta-based dog services provider, has recently ... assists dog owners in creating legally-enforceable pet trusts for their canine companions. , ... to protect their new companion. Says Evan Dunbar, CEO of Full Contact K9, “When ...
(Date:3/29/2017)... ... , ... Sports Brand EXOUS Bodygear announced today a special sale price for ... remaining days of March, the price will be only $19.97. The EXOUS Bodygear 65cm ... $10 (regular retail price $19.97). , The special promotional prices are to help individuals ...
(Date:3/29/2017)... Carnegie, OK (PRWEB) , ... March 29, 2017 ... ... can now receive FASTBRACES® in Carnegie, OK, from Dr. Jamie Cameron, ... to straighten teeth efficiently, compared to traditional orthodontic treatment. Depending on each patient’s ...
(Date:3/29/2017)... ... March 29, 2017 , ... Curio Wellness , ... announce the finalization of the company’s executive management team with prominent executives from both ... is Curio Wellness’ Chief Operating Officer, Ted Dumbauld , who has more than ...
(Date:3/29/2017)... ... March 29, 2017 , ... Hamlin Dental Group, multi-location dental office ... laser dental treatments. Dental lasers are safe and effective options, and can be used ... can improve the overall quality of care. , Dr. Hamid Reza of Hamlin Dental ...
Breaking Medicine News(10 mins):